Integra Therapeutics Showcases Gene-Writing Platform at ASGCT Annual Meeting
Integra Therapeutics presented its FiCAT gene-writing platform at the 29th Annual Meeting of the American Society for Gene and Cell Therapy in Boston. The platform demonstrated the ability to insert multiple genes into a genome safely and efficiently, a significant advancement over traditional methods. This technology aims to improve the development of CAR-T cell therapies by offering precise gene insertion, reducing risks associated with random integration. The presentation highlighted the potential of FiCAT to enhance the safety and efficacy of treatments for autoimmune and oncological diseases, marking a step forward in gene therapy innovation. 
